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Tuberculosis (TB) remains a leading cause of mortality amongst infectious diseases worldwide. 
InhA, an enoyl ACP-reductase, has been the focus of numerous drug discovery efforts as this 
is the target of the first line pro-drug isoniazid.  However, with resistance to this drug becoming 
more common the aim has been to find new clinical candidates that directly inhibit this enzyme 
and that do not require activation by the catalase peroxidase KatG, thus circumventing the 
majority of the resistance mechanisms. In this work, the screening and validation of a fragment 
library is described and development of the fragment hits using a fragment growing strategy 













Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains 
the deadliest infectious disease worldwide, with approximately 10.4 million affected cases and 
1.7 million deaths per year.1 The emergence of a number of multidrug-resistant TB (MDR-TB) 
and extensively drug resistant (XDR) strains as well as a deadly synergy with HIV1 present 
many challenges. Despite recent successes in identifying new chemical entities to combat TB 
and the prospect of new regimens that will shorten TB treatment from the current six months, 
there remains an urgent need to find new drugs to fight this disease. 
Mycolic acids, synthesized by the fatty acid synthase complex II (FAS II), are essential 
components of the unique cell envelope of mycobacteria. The essentiality of this pathway is 
explored clinically by isoniazid (INH), a first-line drug, and ethionamide (ETH), a second-line 
drug used to treat MDR-TB. Both of these drugs target the FAS II enzyme InhA, an NADH 
dependent enzyme involved in the reduction of long-chain fatty acids. Both INH and ETH are 
pro-drugs that need to be activated within the mycobacteria to form a covalent adduct with the 
nicotinamide adenine dinucleotide (INH-NAD adduct), which binds strongly into the catalytic 
site of InhA.2 Resistance to these two pro-drugs can be predominantly explained by mutations 
in the activating enzymes (KatG for INH and EthA for ETH) or in the upstream promoter 
region of InhA, and less commonly in InhA itself due to the essentiality of the enzyme.2 Many 
recent drug discovery efforts have focused on several of the enzymes of this pathway such as 
KasA3, Pks134, 5, Ag85C6, 7 and FadD328 with InhA receiving most of the attention.9-13 
InhA has been a major target for TB drug discovery with many novel and diverse potent 
inhibitors which includes triclosan derivatives, pyridomycin, 4-hydroxy-2-pyridones, 
thiadiazoles, proline series, pyrrolidine carboxamide which have been reported in the literature. 
These inhibitors show direct inhibition of InhA without the need for activation, thus 
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circumventing the most common resistance mechanism to the current drugs targeting this 
enzyme.13 
 In this work, fragment-based drug discovery (FBDD) was used as an alternative 
approach to previous reported drug discovery methods for InhA, where the aim is to find novel, 
potent inhibitors of the enzyme. FBDD is now established as a powerful tool to discover small-
molecule ligands or fragments as hits, which are further elaborated into lead compounds for 
drug development and this approach has been widely used in the TB field..14, 15 Researchers at 
the University of Dundee recently reported the screening of a fragment library against InhA, 
however, further development of the fragment hits has not yet been reported.16 Herein, a three-
stage biophysical screening cascade: thermal shift, ligand-based NMR and X-ray 
crystallography led to the identification of several fragment hits. Using a fragment growing 
strategy supported by enzymatic assays, X-ray crystallography and molecular docking, one 
fragment, which displays a novel binding mode in the X-ray crystal structure, was further 
elaborated into a new class of nanomolar inhibitors of InhA. 
 
Results and discussion 
Fragment screening cascade 
Differential scanning fluorimetry (DSF) was used to screen an in-house library of 800 rule-of-
three-compliant fragments. A saturating concentration of the co-factor in oxidized form (1 mM 
NAD+) was used in all the experiments to ensure that the co-factor binding site would be 
occupied by NAD+ and that fragments would not bind there. InhA was shown to have a melting 
temperature (Tm) of 53˚C in the presence of 1 mM NAD+. Triclosan, a known inhibitor of 
InhA17, was used as a positive control, and presented a thermal shift (∆Tm) of +3.0˚C with a 
melting temperature of 56˚C at a concentration of 0.5 mM in the presence of NAD+. Upon 
screening of the fragment library, a hit was defined where the melting point was increased by 
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at least +3˚C at a concentration of 5 mM (Figure 1a). A total 42 fragment hits were identified 
using DSF, representing a hit rate of 5.2 % (Table S1).  
 
 
Figure 1. a) Histogram of fragments (5 mM) found to increase the melting point (∆Tm) of InhA 
(10 µM) in presence of NAD+ (1 mM) by fluorescence-based thermal-shift assay. b) Chemical 
structures of the X-ray hits obtained. c) X-ray structure of fragment 1 (teal) bound in an InhA-
NAD+ complex (grey), showing cavity surface. The substrate binding regions of InhA are 
divided into three sites - site I, site II and site III. Fragment 1 occupies the catalytic site I and a 
part of the hydrophobic pocket site II and Y158 adopts an “in” conformation. d) Overlaid X-
ray crystal structures of fragments 1 (green) and 3 (magenta), binding to InhA in the presence 
of NAD+ with Y158 in an open conformation for fragment 1 (cyan, PDB Code 6SQ5) and in a 




In order to validate the hits obtained in the thermal shift assay, ligand-based NMR 
techniques, CPMG (Carr-Purcell-Meiboom-Gill, which examines the T2 relaxation in the 
presence of the protein), , WaterLOGSY (which examines the transfer of magnetization from 
the bulk water molecules in the protein to the ligand) and STD (Saturated transfer difference, 
which involved the selective saturation of protein resonances and subsequent transfer of 
magnetisation) were used.18-20  The fragments were screened at a concentration of 1 mM, in 
presence of NAD+ (0.5 mM), with 20 µM InhA using three techniques. Eighteen fragments 
showed interactions with InhA in at least two ligand-based NMR techniques and these were 
considered as confirmed hits. The validated hit rate was 42 % in which 83% (15 fragments) 
contained carboxylic acids (Table S1). 
The eighteen fragment hits validated by NMR were then soaked into InhA crystals and 
X-ray diffraction data was collected. Of these fragments, five showed sufficiently clear electron 
density in the X-ray crystal structures that allowed them to be modelled with confidence 
(Figure 1b and S1).  
The binding pocket of InhA inhibitors that are substrate-competitive can be divided into 
three distinct sites that have different properties, site I being the catalytic site, site II a 
hydrophobic region that binds fatty acid chains and site III a solvent exposed site that is known 
as the size-limiting region (Figure 1c).21 All of the obtained X-ray crystal structures of the 
fragments contain NAD+, and the compounds occupy the same area as the InhA substrate 
covering regions of sites I and II. The X-ray data collection and refinement statistics are 
reported in Table S2. In the X-ray crystal structures of all the initial fragments, with the 
exception of compound 3, Y158 adopts a previously described conformation known as “Y158-
in” (Figure S2). The “Y158-in” conformation has previously been observed with InhA 
inhibitors (triclosan, 4-hydroxypyridones and pyrrolidine carboxamides) where the hydroxy 
group of Y158 is oriented toward the inhibitor in site I. The aromatic group of the fragments 
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occupies the hydrophobic site II of InhA pocket (Figure 1c and S2).13 For compounds 1, 4 and 
5, the carboxylic acid portion of the molecules superimposes completely and forms hydrogen 
bonds with the hydroxyl group of the ribose and Y158 while compound 3 only forms hydrogen 
bonds with the ribose hydroxyl group (Figure S2). Compound, 3, presented a unique mode of 
binding as the Y158 residue showed a distinct conformation from all other X-ray crystal 
structures in both this study and in the literature (Figure 1d). This compound was observed to 
be sandwiched between the residues Y158 and F149 forming π interactions with both (Figure 
S2). For compound 2, even though the carboxylic acid group forms similar interactions as 
compounds 1, 4 and 5 it sits in a different position with its benzo-moiety facing away from the 
ribose and occupying a similar area of the InhA site as the imidazole group of compound 5.  
The identified fragment hits were further evaluated by an InhA enzymatic assay using 
the 2-trans-octanoyl-CoA as a substrate.22 The fragments were screened in triplicate at a final 
concentration of 2 mM using triclosan as a positive control. However, none of the fragments 
displayed any inhibitory activity against InhA at a concentration of 2 mM. 
 
Fragment growing 
The examination of the X-ray structures of the fragments 1-5 supported the feasibility 
of a fragment growing approach. The carboxylate group in site I provided a good handle for 
elaboration towards the site II of the InhA pocket (Figures 1c). Based on the novelty of the 
fragment hits and the vectors available to grow the fragments, fragment 1 was selected for 
further elaboration.  
The X-ray crystal structure of triclosan was overlaid with the structure of fragment 1 
and it showed a similar binding mode to the fragment in the enzyme-NAD+ complex (Figure 
2a). The carboxylate of fragment 1 occupies the same region of the triclosan phenyl-ether 
linker.17 The carboxylic acid in fragment 1 (P1) was replaced by an isosteric sulfonamide 
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replacement, as a linker to synthesize compound 6 (Figure 2B). Docking experiments with 
Glide XP 23 (Schrodinger LLC), using the X-ray crystal structure of InhA with fragment 1 as a 
model, showed that the sulfonamide vector also provided the right geometry to grow the 
fragments into the InhA site III while also forming hydrogen bonds with Y158 and NAD+ 
(Figure 3a and 3b), with compound 6 showing a significant improvement of the activity (54% 
inhibition (100 µM)). All the synthesized compounds were tested at a concentration of 100 µM 
using the InhA enzymatic assay. The IC50 were determined only for the compounds showing 
an inhibitory activity greater than 90% under these screening conditions. 
 
 
Figure 2: A) X-ray crystal structure of fragments 1 (PDB code 6SQ5)  overlayed with triclosan 
(PDB code 2B35) bound to the InhA-NAD+ complex with “Y158-in” conformation. B) 
Fragment growing strategy from fragment 1 to compound 6. Inhibition percentage of InhA 




The phenyl ring was replaced by a piperidine saturated ring which could be useful to 
grow fragment 1 into site III. This modification led to loss of potency in compound 7 (15% 
inhibition at 100 µM, Table 1). The introduction of a pyridine ring also displayed a lower 
percentage inhibition (17%) for compound 8. Therefore, the phenyl ring of compound 6 was 
maintained and analogues of compound 6 were prioritised.  
 
Table 1. Structure and activities of compounds 7-20 evaluated by an enzymatic assay 
 
Compound R1 
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13  24 20  0 
aLigand efficiency LE: Compound 14 = 0.29, compound 19 = 0.31 c 
a Inh% : inhibition percentage at 100 µM concentration. b IC50 : measured in µM 
by enzymatic assay from an average of three experiments. IC50 values were 
determined for compounds that showed >90% inhibition at 100 µM. c LE was 
calculated using the equation LE = (1.37 × pIC50)/HA, where HA means heavy 











As shown in Table 1, compounds 9 and 10 did not add any improvement where a percentage 
inhibition of 0% and 11% was measured respectively. Subsequent deprotection of compound 
10 to afford the aniline 11, also did not show any improvement in the percentage inhibition 
(6%).  This was also observed with the electron-donating methoxy group in compound 12.  The 
benzyl ester 13 (% Inhibition = 24%) showed a better potency than the previous analogues 
although this was still low.    
Interestingly a 10-fold increase of the potency from compound 6 was observed with the 
synthesis of benzylamine analogue 14 (Table 1). This compound  showed an improved InhA 
inhibition (>90%) with an IC50 of 9 µM and a ligand efficiency (LE) of 0.29, which is at least 
a 200-fold more potent compound compared to the initial fragment hit 1 (IC50 > 1000 µM).  
 
 


















Method A: NEt3, DCM


























28 R = 4-CH2NHBoc
29 R = 3-CH2NHBoc
14 R = 4-CH2NH2




Scheme 1: Synthesis of compounds substituted on the sulphonamide group 
 
Subsequently, compounds 15 to 20 were synthesized as analogues of compound 14 to 
explore whether the primary amine could be replaced by other functional groups (Table 1). In 
compounds 15 and 16, the amine of compound 14 was respectively mono-methylated and 
acetylated. The amine was replaced by a carboxylic acid and an acetamide group in the 
analogues 17 and 18. All these modifications on this position of the methyleneamine of 
compound 14 led to a loss of potency with an InhA percentage inhibition between 0 and 25% 
at a ligand concentration of 100 µM. Inhibition of InhA was slightly improved (9 µM compared 
to 4 µM) by moving the methylamine to the meta-position, compound 19 and gave an IC50 of 
4 µM and a LE of 0.31. The docking pose of compound 19 showed the amine group forms a 
hydrogen bond with the phosphate of NAD+ and forcing the phenyl ring to move further away 
from the phosphates towards M161 (Figure 3c and 3d). This changes the orientation of the 
sulfonamide now only forming an hydrogen bond with Y158 and it further alters the position 




Figure 3: Docking poses for compounds 6 (A) and 19 (C) superposed with fragment 1 (green). 
Hydrogen bonds for each for compound 6 and 19 and shown as red dashes respectively in (B) 
and (D) with distances in Å. The compounds 6 and 19 were docked into the structure for 
fragment 1 (PDB code 6SQ5). 
 
The activity was lost in compound 20 in which the amine is part of a closed 6-membered 
ring. The development of compounds 15-20 showed that the phenylmethanamine group was 
crucial to maintain affinity and was maintained for further development of a potent InhA 
inhibitor. Subsequently, the sulfonamide with the phenylmethanamine scaffold on P3 (Table 






Further Elaboration strategies 
The trifluoromethyl styrene moiety in compound 19 could potentially be metabolized 
to styrene oxide,  and as a result this scaffold was replaced to improve the drug-like properties. 
From the X-ray crystallography of the parent fragment 1 and from molecular docking, P2 of 
compound 19 should mainly occupy the hydrophobic site II of InhA (Figure 3c). However, 
docking studies of derivatives of 1 showed that the trifluoromethyl styrene moiety could bind 
to different hydrophobic areas of site II (Figure 3a and 3c). Hydrophobic functional groups 
were chosen as modifications at P2 of compound 19 (Table 2). The tert-butylphenyl and chloro-
naphthalene groups in compound 21 and 22 were synthesized based on similarities with 
respectively fragments 2 and 4. However both compounds 21 and 22 showed a drop of 
percentage inhibition to 40% and 17% respectively at a screening concentration of 100 µM. 
 
 
Scheme 2: Exploration of SAR based on compound 19.  
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0.31 (LE 0.40)c 
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> 90  
0.25 (LE 0.40) c 
25 
 
> 90  6.0  
26 
 
66  22.0 
a Inh% : inhibition percentage at 100 µM concentration. b IC50 : measured in µM by enzymatic 
assay from an average of three experiments. IC50 values were determined for compounds that 
showed >90% inhibition at 100 µM. c LE was calculated using the equation LE = (1.37 × 
pIC50)/HA, where HA means heavy atom, i.e., a non-hydrogen atom 
 
 
The introduction of a 5-chloro-3-methylbenzothiophene in compound 23 improved the 
InhA inhibition IC50 to a value of 310 nM with a ligand efficiency of 0.40. This is a 12-fold 
jump in potency in comparison to compound 19, (Table 2). The replacement of the 5-chloro 
with a 5-fluoro substituent in compound 24 slightly improved the potency to 250 nM. The 
halogens and methyl substitutions prove to be essential for the activity as a significant drop in 
activity to 6 and 22 µM were observed respectively for compounds 25 and 26 (Table 2). This 




Figure 4. a) X-ray crystal structure and interaction map of compound 23 (PDB Code 6SQL). 
NAD+ is shown in white while compound 23 in shown in teal. Red disks represent hydrogen 
bonds, blue disks depict π-π interactions, yellow disks sulphur-π. Interactions were calculated 
using Intermezzo plugin for Pymol (Ochoa B., et al. unpublished). b) Substrate binding region 
of InhA divided into three sites. The X-ray structure of fragment 1 (violet) (PDB code 6SQ5) 
is overlaid with compound 23, showing cavity surface. 
 
The X-ray crystal structure for compound 23 was obtained (Figure 4a) and it shows, as 
predicted by docking (Figure S3), that the sulfonamide group forms an hydrogen bond with 
Y158 and has the correct orientation for the phenylmethanamine moiety to explore site III 
forming π-interactions with the backbone of the protein at G96 and a sulphur-π interaction with 
M161 (Figure 4a and 4b). Furthermore, the amine in the meta-position of the phenyl ring 
interacts with the phosphates of NAD+, but also with a highly coordinated water that further 
interacts with the sulfonamide group and the NAD+ phosphate (Figure 4a). The benzothiophene 
group forms π-interactions with F149 and Y158, sulphur-π interactions with M103, M155 and 
M199 while exploring a different hydrophobic area on site II, (Figure 4b). The position of the 
phenylmethanamine group in relation to the sulfonamide is crucial for the binding affinity.  In 
the earlier SAR examined in Table 1 when this was changed to a secondary amine (compounds 
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15 and 20) or an aniline (compound 11) there little or no binding observed. This could be due 
to the increased sterics observed in compound 15 and 20 which would not allow the H-bonding 
interactions. With compound 11 the intramolecular H-bonding interactions through the water 
would not be possible due to the direct attachment of the NH2 group to the benzene ring.  
 
Evaluation of the effects of InhA inhibitors on mycolic acid synthesis in M. tuberculosis 
H37Ra 
 The IC50 of tested inhibitors against InhA protein were promising and these compounds 
(14, 19 and 23-26) were screened to see whether they can inhibit the growth of M. tuberculosis. 
Further analysis of the effect on the synthesis of mycolic acids by metabolic labeling24, 25 of 
the model strain M. tuberculosis H37Ra with 14C acetate was also explored. A 48 h cultivation 
in the presence of 200 µM of the compounds in the media led to 84 % growth inhibition for 
compound 19; 40 and 33% growth inhibition for compounds 14 and 23, respectively; 38 % 
growth inhibition for compound 24 and isoniazid; and 23 % growth inhibition for compounds 
25 and 26. However, while the presence of isoniazid caused complete abolition of synthesis of 
mycolic acids, only slight inhibition was observed in the case of compound 19 and no inhibition 




Figure 5. a) TLC of the metabolic labeling experiments of M. tuberculosis H37Ra with 14C 
acetate treated with the compounds 14, 19 and 23-26 for the analysis of mycolic acids 
inhibition. Fatty acid methyl esters – FAME; mycolic acid methyl esters – MAME and 
isoniazid – INH. b) TLC of the metabolic labeling experiments of M. tuberculosis H37Ra with 
14C acetate treated with the compounds 14, 19 and 23-26 for the analysis of the lipid inhibition. 
Trehalose monomycolates – TMM; trehalose dimycolates – TDM; phosphatidylethanolamine 
– PE; cardiolipin - CL and isoniazid – INH. 
 
The analysis of lipid profiles revealed that treatment with compound 19 led to the 
accumulation of TMM and to the decrease of amount of TDM (Figure 5b). None of other tested 
inhibitors affected the amounts of TMM and TDM in mycobacterial cells suggesting that 
despite the potent IC50 values, the tested compounds possibly do not target InhA inside 
mycobacterial cells and further experiments are needed in order to clarify this. 
 
Conclusions 
Fragment-based drug discovery is a robust and now widely used approach to identify 
drug-like molecules and this methodology has led to the development of a number of drugs 
which have been approved by the FDA. In this work we identified several fragment hits using 
a screening cascade consisting of DSF, ligand-based NMR and X-ray crystallography. The 
initial fragment hits revealed a ligand having a unique binding mode and forcing Y158 to adopt 
a new conformation that “sandwiches” the compound between the residues F149 and Y158. 
However, the fragment hits had no detectable inhibitory activity. Using the available structural 
information, potent and novel nanomolar inhibitors of InhA were developed applying a 
fragment-growing approach. The systematic exploration of chemical space in P3 and P1 after 
fixing P2 with a sulfonamide and helped by molecular docking led to the development of 
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potency and increase of ligand effiency. The introduction of a benzothiophenene at P2 and the 
phenylmethanamine at P3 led to the development of compound 23 and this was shown to be a 
potent inhibitor of InhA. However, disappointingly compound 23 was shown to be inactive 
against M. tuberculosis.  
In the past decade the TB drug discovery field has seen a shift from target-based 
approaches back to whole-cell phenotypic screens due to the problems faced by compounds 
derived from target-based approach in translating their activity into cell-based assays15. 
However, the number of lead compounds coming from these large-scale screens has been lower 
than expected. The compounds in this study illustrate the current challenge of obtaining new 
antitubercular compounds. The strong InhA inhibitory activity of compounds described herein 
is not reflected in antitubercular activity, nor do we observe a significant reduction in the 
amount of mycolic acids produced by any of the compounds suggesting that the compounds 
do not penetrate the cells in sufficient amounts, are being extruded by efflux mechanisms or 
are metabolized. Further work is required to clarify the nature of the problem and to improve 
the cellular activity of the lead compounds. 
 
Experimental section 
Protein purification, crystallization data collection and refinement 
Mycobacterium tuberculosis InhA was purified as described previously.26 Briefly, E. coli 
BL21(DE3) containing an hexahistidine-SUMO tagged InhA construct in pET28a was grown 
to mid-exponential growth phase (OD610 = 0.8) in LB media (Invitrogen) containing 30 mg L-
1 kanamycin at 37 ºC. Gene expression, was induced by adding Isopropyl β–D-1-
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM and the temperature lowered 
to 18ºC. Cells were lysed in 50mM HEPES pH 7.5, 0.5 M NaCl, 10% glycerol (w/v), 20 mM 
Imidazole and recombinant InhA was purified with a HiTrap IMAC Sepharose FF column 
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(GE-Healthcare), equilibrated in the same buffer. Elution was performed with 500 mM 
Imidazole. The recovered protein was dialysed into 50 mM HEPES pH 7.5, 0.5 M NaCl and 
10% glycerol (w/v) and SUMO tag was cleaved overnight at 4 ºC by adding Ulp1 Protease at 
1:100 ratio. SUMO tag, Ulp1 protease and uncleaved SUMO-InhA were removed using the 
same column, equilibrated with 50 mM HEPES pH 7.5, 0.5 M NaCl, 10% glycerol (w/v) and 
20mM Imidazole. Flow through containing InhA was collected, concentrated and loaded in a 
Superdex 200 column equilibrated with 50mM HEPES pH7.5 150 mM NaCl and 10% glycerol 
(w/v). Fraction purity was determined by SDS-page. The purest fractions were pooled, 
concentrated to ~12 mg.ml-1, flash frozen in liquid nitrogen and stored at -80 ºC.  
InhA was crystallized in the presence of 2 mM NAD, at 18 ºC using the sitting drop vapor 
diffusion method by mixing 1 µL of InhA at 12 mg.mL-1 in a 1:1 ratio with reservoir solution 
containing 0.1 M HEPES pH 7.0, 0.1 M sodium acetate and 25-30% PEG 400. Fragment 
soaking was performed at by mixing compound solution at 200 mM in 100% DMSO with 
mother liquor to a final concentration of 20 mM. Crystals were soaked in these solutions 
overnight. Compound 24 and 2-trans-octanoyl-CoA were co-crystalized by mixing InhA 10 
mg.mL-1 with 0.5 mM NAD+ and 0.5 mM compound 24 or 5 mM 2-trans-octanoyl-CoA in a 
1:1 ratio with reservoir solution containing 14% PEG 4k, 200 mM ammonium acetate, 100 
mM HEPES pH 7 for compound 23 and 10% PEG 8k, 100 mM TRIS pH 8.5 for 2-trans-
octanoyl-CoA. A cryogenic solution was prepared by adding 30% glycerol to mother liquor 
and crystals were briefly transferred to this solution, flash frozen in liquid nitrogen and stored 
for data collection. All datasets were collected at stations i03 and i04-1 at Diamond Light 
Source (Oxford, UK). Data collection and refinement statistics are summarized in (Table S2). 
Diffraction data were indexed, integrated and reduced using autoPROC from Global Phasing 
Limited 27. Molecular replacement was performed with Phaser 28 using PDB structure 2B35 as 
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a search model. Refinement was carried out iteratively with PHENIX 29 and Coot 30, and ligand 
and water fitting was performed with Coot. 30 
 
Molecular docking 
Glide XP23 (extra precision) included in the Schrodinger software package (Schrodinger, LLC, 
New York, NY, 2015 and 2016) was employed for docking of compounds using the X-ray 
crystal structure with fragment 1 as the receptor. Epik31, included in the same software package 
was used to prepare ligands. Docking was performed using default XP settings, with flexible 
ligand sampling and post-docking minimization. 
 
Differential scanning fluorimetry 
Differential scanning fluorimetry was used to screen a library of 800 fragments. The assay was 
performed in a 96 well plate format using a CFX Connect (Bio-Rad). Each well contained a 
solution of 10 µM InhA, 1mM NAD+, Hepes (50mM), NaCl (150 mM), pH 7.5, 5x Sypro 
Orange, 5% DMSO and fragments at 5mM. A positive control with 0.5 mM Triclosan was 
included in all plates. Controls were made in quadruplicates for all the experiments. 
 
Enzymatic assay  
InhA activity was followed by a colorimetric assay that measured the oxidation of NADH at 
340 nm in the presence of 2-trans-octanoyl-CoA as described before in a buffer that contained 
30 mM PIPES pH 7.5, 50 mM NaCl and 0.1 mM EDTA. InhA (100 nM). 26 This was pre-
incubated for 10 min at room temperature with 0.25 mM NADH and varying concentrations of 
the compounds at a with 1% (v/v) DMSO in 150 µL reaction volume. The reaction was started 
by the addition of 2-trans-octanoyl-CoA at a final concentration of 1.5 mM prepared as 
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described previously. 22 Reactions were followed for 20 min using a plate reader (CLARIOstar 
- BMG LABTECH). 
 
Analysis of effects of tested compounds on mycolic acid synthesis in M. tuberculosis 
H37Ra 
The culture of M. tuberculosis H37Ra was grown statically at 37°C in Middlebrook 7H9 broth 
(Difco) supplemented with albumin-dextrose-catalase and 0.05% Tween 80. When the culture 
reached the value of O.D.(600 nm) 0.290, it was divided into 10 mL aliquots and tested 
compounds dissolved in DMSO were added in 200 µM final concentrations, while isoniazid 
that served as a control inhibitor was at 40 µM. The final concentration of DMSO in each 
culture was at 1 %. After 24 h of cultivation with shaking (120 rpm) in the presence of tested 
inhibitors, 14C acetate (specific activity 106 mCi/mmol, ARC) was added in the final 
concentration of 0.5 μCi/mL and the cells were cultivated for next 24 h. 
Lipids were extracted from whole cells as described earlier with minor modifications. 24 
Briefly, 3 mL chloroform/methanol (1:2) were added to cells harvested from 4 mL culture 
aliquots, the mixtures were incubated at 56°C for 1.5 h with intense mixing, centrifuged at 
1000 x g and the extracts were collected in glass tubes. This was followed by the extraction 
with chloroform/methanol (2:1) at the same conditions. Both extracts were combined together, 
dried under nitrogen and subjected to biphasic wash with chloroform/methanol/water (4:2:1) 
as described earlier.25 The bottom organic phase was dried and dissolved in 
chloroform/methanol (2:1), 250 μL per 1 unit of O.D.(600) of harvested cells. 5 μL of each 
lipid sample were loaded on the thin-layer chromatography (TLC) silica gel plates F254 




 Fatty acid methyl esters (FAME) and mycolic acids methyl esters (MAME) were 
prepared from whole cells harvested from 4 ml culture aliquots as previously described.32 Dried 
extracts were dissolved in chloroform/methanol (2:1) in the ratio 250 μL per 1 unit of (O.D. = 
600) of harvested cells and 5 μL of each sample were loaded on TLC plates. Different forms 
of methylesters were separated by chromatography in n-hexane/ethyl acetate [95:5], 3x and 
detected by autoradiography. 
 
Synthetic chemistry 
General Experimental Methods. Solvents were distilled prior to use and dried by standard 
methods. Unless otherwise stated, 1H and 13C NMR spectra were obtained in CDCl3, MeOD, 
or DMSO solutions using either a Bruker 400 MHz AVANCE III HD Smart Probe, 400 MHz 
QNP cryoprobe, or 500 MHz DCH cryoprobe spectrometer. Chemical shifts (δ) are given in 
ppm relative to the residual solvent peak (CDCl3: 1H, δ = 7.26 ppm; 13C, δ = 77.16 ppm), and 
the coupling constants (J) are reported in hertz (Hz).  
Reactions were monitored by TLC and LCMS to determine consumption of starting materials. 
Flash column chromatography was performed using an Isolera Spektra One/Four purification 
system and the appropriately sized Biotage SNAP column containing KP-silica gel (50 μm). 
Solvents are reported as volume/volume eluent mixture where applicable. 
High resolution mass spectra (HRMS) were recorded using a Waters LCT Premier Time of 
Flight (TOF) mass spectrometer or a Micromass Quadrapole-Time of Flight (Q-TOF) 
spectrometer. 
Liquid chromatography mass spectrometry (LCMS) was carried out using an Ultra 
Performance Liquid Chromatographic system (UPLC) Waters Acquity H-class coupled to a 
Waters SQ Mass Spectrometer detector. Samples were detected using a Waters Acquity TUV 
detector at 2 wavelengths (254 and 280 nm). Samples were run using an Acquity UPLC HSS 
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column and a flow rate of 0.8 mL/min. The eluent consisted of 0.1% formic acid in water (A) 
and acetonitrile (B); gradient, from 95% A to 5% A over a period of 4 or 7 min. All final 
compounds had a purity greater than 95% as determined by LCMS analysis. 
 
(E)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonyl chloride (27). Sulfuryl chloride (3.8 mL, 
46 mmol) was added dropwise at 0 °C to a solution of anhydrous DMF (10 mL) under N2. 
After the addition was completed, the mixture was warmed to r.t. and stirred further for 0.5 h. 
1-(trifluoromethyl)-3-vinylbenzene (1.71 mL, 11 mmol) was then added in three portions and 
the reaction mixture was gradually heated at 90°C for 3h. The reaction mixture was cooled and 
then poured onto the crushed ice and the separated oily layer was extracted with Et2O and dried. 
Evaporation of the solvent gave the desired compound 27 (77% yield) as a yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 7.94 – 7.48 (m, 3H), 4.43 – 4.25 (m, J = 14.2, 5.5 Hz, 1H), 3.85 – 
3.71 (m, 1H). LC/MS [mass of sulfonic acid -H] found 251.1. 
 
(E)-N-phenyl-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (6). To a solution of 
compound 27 (50 mg, 0.185 mmol) in DCM (5.0 mL), dry triethylamine (0.031 mL, 0.22 
mmol) was added aniline (17 mg, 0.18 mmol). The reaction mixture stirred for 3 hours at room 
temperature. The reaction was quenched with saturated solution of NaHCO3, followed by 
extraction with DCM. The organic phase was dried on anhydrous MgSO4, concentrated under 
reduced pressure and the crude product purified by silica flash column chromatography 
(column gradient of 20% to 50% EtOAc in Pet. Ether 40-60 oC) to yield the desired product 
(32 mg, 53% yield) as a white powder. 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.58 – 7.45 
(m, 2H), 7.35 – 7.22 (m, 3H), 7.14 (t, J = 7.2 Hz, 1H), 6.92 (d, J = 15.5 Hz, 1H). HRMS (ESI) 





(E)-N-(piperidin-4-yl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (7). Using the same 
procedure as compound 6, tert-butyl-4-aminopiperidine-1-carboxylate (0.100 g, 0.37 mmol) 
and 27 (0.100 mg, 0.37 mmol) yielded the Boc-protected intermediate tert-butyl-(E)-4-((2-(3-
(trifluoromethyl)phenyl)vinyl)sulfonamido)piperidine-1-carboxylate (78 mg, 0.37 mmol, 78% 
yield) as a white powder. The crude product was purified by silica flash column 
chromatography (column gradient of 30% to 60% EtOAc : Pet. ether 40-60 oC 1H NMR (400 
MHz, CDCl3) δ 7.72 (s, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 7.7 Hz, 1H), 7.49 (d, J = 
15.5 Hz, 1H), 6.86 (d, J = 15.4 Hz, 1H), 4.90 (d, J = 7.5 Hz, 1H), 3.94 (m, 2H), 3.52 – 3.26 (m, 
1H), 3.02 – 2.69 (m, 2H), 1.92 (m, 2H), 1.51 – 1.43 (m, 2H), 1.42 (s, 9H). LC/MS [M-H] found 
433.2, purity >99 %. 
To a solution of the Boc intermediate in dichloromethane (2 mL), trifluoroacetic acid (1 mL) 
was added dropwise and the mixture stirred for 0.5 hours. The reaction was quenched with 
saturated solution of NaHCO3. The organic phase was seperated, and the solvent removed 
under reduced pressure to yield the product (45 mg, 0.18 mmol, 75% yield) as yellow oil. 1H 
NMR (400 MHz, DMSO-d6) δ 1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H), 8.04 (d, J = 7.8 
Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 1.7 Hz, 1H), 3.19 (m, 
2H), 2.88 (m, 1H), 2.00 – 1.88 (m, 1H), 1.61 (m, 1H). HRMS (ESI) calcd. for [C14H17F3N2O4S 
+ H]+: 335.1041, Found: 335.1053. LCMS [M+H]+ found 335.1, purity >99 %. 
 
(E)-N-(pyridin-3-yl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (8). To a solution of 
compound 27 (50 mg, 0.18 mmol) in DCM (5.0 mL), dry Et3N (0.03 mL, 0.220 mmol) was 
added 3-aminopyridine (17 mg, 0.18 mmol). The reaction mixture was stirred for 3 hours at 
room temperature. The reaction was quenched with NaHCO3, followed by extraction with 
DCM. The organic phase was dried on anhydrous MgSO4, concentrated under reduced pressure 
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and the crude product purified by silica flash column chromatography (column gradient of 20% 
to 50% EtOAc : Pet. Ether 40-60 oC) to yield the desired product (39 mg, 64% yield) as a white 
powder. 1H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 3.3 Hz, 1H), 8.70 (dd, J = 4.8, 1.5 Hz, 
1H), 8.25 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.03 (ddd, J = 8.2, 2.6, 1.5 Hz, 1H), 7.93 (d, J = 
15.3 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.77 – 7.64 (m, 2H), 7.59 (dd, J = 8.2, 4.0 Hz, 1H), 1.23 
(s, 1H); LCMS: no molecular ion peak observed, purity 97% ; HRMS (ESI) calcd. for 
[C14H11N2O2F3S + H]+: 329.0572, Found: 329.0563. 
 
Methyl (E)-4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)benzoate (9). Using the same 
procedure as with compound 6, methyl 3-aminobenzoate (0.168 g, 1.108 mmol) and compound 
27 (0.300 g, 1.108 mmol). The crude product was purified by silica flash column 
chromatography (column gradient of 20% to 50% EtOAc : Pet. ether 40-60 oC) which yielded 
the desired product 9 (0.281 g, 0.729 mmol, 66% yield) as a yellow powder. 1H NMR (400 
MHz, CDCl3) δ 7.88 (d, J = 2.0 Hz, 1H), 7.82 (dd, J = 7.7, 1.3 Hz, 1H), 7.65 (d, J = 7.7 Hz, 
2H), 7.63 – 7.54 (m, 1H), 7.55 – 7.46 (m, 2H), 7.41 (t, J = 7.9 Hz, 1H), 7.16 (s, 1H), 6.88 (d, J 
= 15.4 Hz, 1H), 3.91 (s, 3H), 3.50 (s, 1H); HRMS (ESI) calcd. for [C17H14F3NO4S+H]+: 
386.0674, Found: 386.0688; LCMS: [M-H]- found 384.1, purity 94%. 
 
tert-butyl-(E)-(4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)phenyl)carbamate (10). 
Using the same procedure as compound 6, tert-butyl (4-aminophenyl)carbamate (77 mg, 0.37 
mmol) and compound 27 (100 mg, 0.37 mmol). The crude product was purified by silica flash 
column chromatography (column gradient of 30% to 60% EtOAc : Pet. ether 40-60 oC). This 
yielded the desired product (50 mg, 0.050 mmol, 31% yield) as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 7.64 (d, J = 6.0 Hz, 2H), 7.57 (d, J = 8.2 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.43 (d, J 
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= 15.5 Hz, 1H), 7.31 (d, J = 8.8 Hz, 2H), 7.20 – 7.11 (m, 2H), 6.90 – 6.80 (m, 2H), 6.54 (s, 
1H), 1.49 (s, 9H); LCMS: [M-H]- found: 441.0, purity > 99%. 
 
 (E)-N-(4-aminophenyl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (11). Using the 
same procedure as compound 7, compound 10 (50 mg, 0.11 mmol) was deprotected to yield 
the desired product (26 mg, 0.070 mmol, 62% yield) as a brown oil. 1H NMR (500 MHz, 
DMSO-d6) δ 8.10 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 7.1 Hz, 1H), 7.63 (t, J = 7.8 
Hz, 1H), 7.53 (t, J = 7.2 Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.35 (d, J = 11.8 Hz, 1H), 6.87 (d, J 
= 8.7 Hz, 1H), 6.46 (d, J = 8.7 Hz, 1H); LCMS: [M-H]- found 341.1, purity >99%. 
(E)-N-(4-methoxyphenyl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (12). Using the 
same procedure as compound 6, 4-methoxyaniline (37 mg, 0.28 mmol) and compound 27 (50 
mg, 0.18 mmol) The crude product was purified by silica flash column chromatography 
(column gradient of 30% to 70% EtOAc : Pet. ether 40-60 oC). This yielded the desired product 
(10 mg, 0.03 mmol, 15% yield) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 9.73 (s, 1H), 
8.13 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.86 – 7.57 (m, 2H), 7.19 – 7.02 (m, 2H), 6.98 – 6.80 
(m, 2H), 6.71 – 6.58 (m, 1H), 6.55 – 6.24 (m, 1H), 3.68 (s, 2H); HRMS (ESI) calcd. for 
[C16H14NO3F3S + H]+: 358.0725, Found: 358.0735. LCMS [M-H]- found 356.1, purity 96% 
 
Methyl-(E)-2-(4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)phenyl)acetate (13). Using 
the same procedure as compound 7, 2-(4-aminophenyl)acetate (46 mg, 0.28 mmol) and 
compound 27 (50 mg, 0.18 mmol) yielded the desired product methyl (11 mg, 0.025 mmol, 
15% yield) as a white powder. The crude product was purified by silica flash column 
chromatography (column gradient of 30% to 60% EtOAc: Pet. ether 40-60 oC). 1H NMR (400 
MHz, Chloroform-d) δ 7.65 (d, J = 6.6 Hz, 2H), 7.59 (d, J = 7.9 Hz, 1H), 7.54 – 7.46 (m, 2H), 
7.23 (d, J = 8.5 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 15.4 Hz, 1H), 6.73 (s, 1H), 3.67 
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(s, 3H), 3.58 (s, 2H); HRMS (ESI) calcd. for [C18H16NO4F3S+H]+: 400.0830, Found: 400.0821 
LCMS: [M-H]- found 398.1, purity >99%. 
 
tert-butyl-(E)-(4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)benzyl)carbamate (28). 
Using the same procedure as compound 7, 4-[(N-Boc)aminomethyl]aniline (82 mg, 0.369 
mmol) and compound 27 (100 mg, 0.369 mmol) yielded the Boc intermediate (138 mg, 0.302 
mmol, 82% yield) as white crystals. The crude product was purified by silica flash column 
chromatography (column gradient of 30% to 60% EtOAc : Pet. ether 40-60 °C). 1H NMR (400 
MHz, Chloroform-d) δ 7.65 (d, J = 6.3 Hz, 2H), 7.60 (d, J = 7.8 Hz, 1H), 7.56 – 7.43 (m, 2H), 
7.23 (d, J = 8.3 Hz, 2H), 7.19 – 7.12 (m, 2H), 6.86 (d, J = 15.5 Hz, 1H), 6.63 (s, 1H), 4.83 (s, 
1H), 4.26 (d, J = 5.7 Hz, 2H), 1.44 (s, 9H); LCMS [M-H]- found 455.1; HRMS (ESI) calcd. for 
[C21H23N2O4F3S+Na]+: 479.1223, Found: 479.1232. 
 
(E)-N-(4-(aminomethyl)phenyl)-2-(3-(trifluoromethyl)phenyl) ethene-1-sulfonamide (14). To a 
solution of the Boc intermediate 28 in dichloromethane (2 mL), trifluoroacetic acid (1 mL) was 
added dropwise and the mixture stirred for 0.5 hours. The reaction was quenched with 
NaHCO3, the organic phase isolated and the final product concentrated under reduced pressure 
to yield the desired product (84 mg, 0.24 mmol, 78% yield) as small yellow crystals. 1H NMR 
(500 MHz, DMSO-d6) δ 8.13 (s, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.64 
– 7.56 (m, 2H), 7.50 (d, J = 15.5 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.23 – 7.13 (m, 2H), 3.88 (s, 
2H), 2.33 (s, 1H); HRMS (ESI) calcd. for [C16H13F3NO2S + H]+: 340.0614, Found: 340.0600; 
LCMS: [M-H]- found 355.1, purity >99%. 
 
(E)-N-(4-((methylamino)methyl)phenyl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide 
(15). Using the same procedure as compound 6, 4-((methylamino)methyl)aniline (25 mg, 0.18 
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mmol) and compound 27 (50 mg, 0.18 mmol) yielded the desired product (36 mg, 0.10 mmol, 
53% yield) as yellow crystals. The crude product was purified by silica flash column 
chromatography (column gradient of 30% to 60% EtOAc : Pet. ether 40-60 oC). 1H NMR (400 
MHz, DMSO-d6) δ 8.04 (d, J = 7.7 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.73 – 7.54 (m, 3H), 7.33 
– 7.12 (m, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.55 (d, J = 8.3 Hz, 2H), 5.25(s, 1H), 4.05 (s, 2H), 
2.60 (s, 3H); HRMS (ESI) calcd. for [C17H17F3N2O2S+H]+: 371.1041, Found: 371.1031; 
LCMS: [M+H]+ found 370.9, purity 87%. 
 
(E)-N-(4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)benzyl)acetamide (16). Using the 
same procedure as compound 6, N-(4-aminobenzyl)acetamide (30 mg, 0.18 mmol) and 
compound 27 (50 mg, 0.18 mmol) yielded the desired product (20 mg, 0.050 mmol, 27% yield) 
as a colourless oil. The crude product was purified by silica flash column chromatography 
(column gradient of 30% to 60% EtOAc : Pet. ether 40-60 oC). 1H NMR (500 MHz, DMSO-
d6) δ 10.08 (s, 1H), 8.24 (t, J = 5.9 Hz, 1H), 8.15 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 
7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.56 (d, J = 15.5 Hz, 1H), 7.50 (d, J = 15.5 Hz, 1H), 7.14 
(t, J = 2.6 Hz, 3H), 4.15 (d, J = 5.9 Hz, 2H), 1.82 (s, 3H); HRMS (ESI) calcd. for 
[C18H17F3N2O3S+H]+: 399.0990, Found: 399.1003 LCMS: [M-H]- found 397.1, purity >99%. 
 
(E)-4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido) benzoic acid (17). Compound 9 (258 
mg, 0.67 mmol) was stirred overnight in 10% LiOH solution in methanol:water (1:1, 4 mL). 
Methanol was removed under reduced pressure then cold water added to the mixture. 1N 
hydrochloric acid was used to precipitate the product, which was filtered and dried to give the 
desired product (174 mg, 0.47 mmol, 70% yield) as a yellow powder. 1H NMR (400 MHz, 
MeOD) δ 7.90 (t, J = 1.9 Hz, 1H), 7.85 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.74 (dt, J = 7.6, 1.4 
Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 15.4 Hz, 1H), 7.46 (ddd, 
29 
 
J = 8.1, 2.3, 1.2 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 15.4 Hz, 1H); HRMS (ESI) calcd. 
for [C16H12F3NO4S+H]+: 372.0517, Found: 372.0502 LCMS: [M-H]- found 370.0, purity 
>99%. 
 
(E)-4-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)benzamide (18). To a solution of 
compound 17 (145 mg, 0.39 mmol), HOBt hydrate (66 mg, 0.43 mmol) and EDCl (82 mg, 0.43 
mmol) in THF (3 mL), N,N  diisopropylethylamine (101 mg, 0.78 mmol) was added and the 
mixture stirred for 10 mins at room temperature. 2M ammonia in methanol (0.195 mL, 0.39 
mmol) was added and the reaction was stirred overnight. NaHCO3:H2O solution (1:1, 3 mL) 
was added, the reaction stirred for 2 hours. The precipitate was filtered to yield the desired 
product 18 (149 mg, 0.389 mmol, 100% yield) as a cream coloured powder. 1H NMR (400 
MHz, MeOD) δ 7.86 (s, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.73 (t, J = 2.0 Hz, 1H), 7.69 (d, J = 7.9 
Hz, 1H), 7.62 – 7.53 (m, 2H), 7.52 (s, 1H), 7.44 – 7.39 (m, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.22 
(d, J = 15.5 Hz, 1H), 2.40 (s, 1H); HRMS (ESI) calcd. For [C16H13F3N2O3S+H]+: 371.0677, 
Found: 371.0681; LCMS: [M-H]- found 369.0, purity 95%. 
 
Tert-butyl (E)-(3-((2-(3 (trifluoromethyl)phenyl)vinyl)sulfonamido)benzyl)carbamate (29). To 
a solution of compound 27 (50 mg, 0.55 mmol) in pyridine (5 mL), tert-butyl(3-
aminobenzyl)carbamate (123 mg, 0.55 mmol) was added and the reaction mixture stirred under 
a nitrogen atmosphere at room temperature for 1 hr. The crude product was concentrated under 
reduced pressure and purified by silica flash column chromatography (column gradient of 30% 
to 60% EtOAc : Pet. ether 40-60 oC) to yield the desired product 29 (175 mg, 0.38 mmol, 69% 
yield) as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 7.68 – 7.56 (m, 3H), 
7.57 – 7.46 (m, 2H), 7.31 – 7.22 (m, 1H), 7.17 (d, J = 9.0 Hz, 2H), 7.05 (d, J = 7.5 Hz, 1H), 
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6.90 (d, J = 15.5 Hz, 1H), 5.03 (s, 1H), 4.28 (d, J = 6.1 Hz, 2H), 1.46 (s, 9H); LCMS: [M-Boc-
H]- found 355.1, purity >99%. 
 
(E)-N-(3-(aminomethyl)phenyl)-2-(3-(trifluoromethyl)phenyl)ethene-1-sulfonamide (19). 
Using the same procedure as compound 14, compound 29 (133 mg, 0.29 mmol) was 
deprotected to yield the desired product 19 (78 mg, 0.22 mmol, 76% yield) as pale yellow 
crystals. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 
7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.55 (d, J = 15.5 Hz, 1H), 7.46 (d, J = 15.5 Hz, 1H), 7.20 
(t, J = 7.8 Hz, 1H), 7.15 (d, J = 1.9 Hz, 1H), 7.05 (dd, J = 8.5, 2.1 Hz, 1H), 6.98 (d, J = 7.6 Hz, 
1H), 3.72 (s, 2H); HRMS (ESI) calcd. for [C16H15F3N2O2S+H]+: 357.0885, Found: 357.0869; 
LCMS: [M-H]- found 355.1, purity >99%.  
 
Tert-butyl-(E)-7-((2-(3-(trifluoromethyl)phenyl)vinyl)sulfonamido)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (30). Using the same procedure as compound 28, tert-butyl 7-amino-3,4-
dihydroisoquinoline-2(1H)-carboxylate (96 mg, 0.38 mmol) and compound 27 (104 mg, 0.38 
mmol) yielded the desired product 30 (148 mg, 0.31 mmol, 80% yield) as pale yellow crystals. 
The crude product was purified by silica flash column chromatography (column gradient of 
20% to 50% EtOAc : Pet. Ether 40-60 oC). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.0 Hz, 
2H), 7.61 (d, J = 7.8 Hz, 1H), 7.56 – 7.48 (m, 2H), 7.08 (d, J = 8.1 Hz, 1H), 6.98 (s, 2H), 6.87 
(d, J = 15.5 Hz, 1H), 5.30 (s, 1H), 4.53 (s, 2H), 3.61 (s, 2H), 2.78 (t, J = 5.7 Hz, 2H), 1.47 (s, 
9H); LCMS: [M-H]- found 481.2, purity >99%. 
 
(E)-N-(1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(3-(trifluoromethyl)phenyl)ethene-1-
sulfonamide (20). Using the same procedure as compound 12, compound 30 (67.2 mg, 0.15 
mmol) was deprotected to yield the desired product (104 mg, 0.28 mmol, 98% yield) as orange 
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crystals. 1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 
7.9 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.58 (d, J = 15.5 Hz, 1H), 7.49 (d, J = 15.5 Hz, 1H), 7.14 
– 7.01 (m, 2H), 6.97 (d, J = 2.0 Hz, 1H), 4.06 (s, 2H), 3.17 (t, J = 6.1 Hz, 2H), 2.78 (t, J = 6.1 
Hz, 2H); HRMS (ESI) calcd. for [C18H17F3N2O2S+H]+: 383.1022, Found: 383.1036; LCMS: 
[M+H]+ found 383.1, purity >99%. 
 
N-(3-(aminomethyl)phenyl)-4-(tert-butyl)benzenesulfonamide (21) Using the same procedure 
as compound 28, 4-(tert-butyl)benzenesulfonyl chloride (100 mg, 0.43 mmol) and tert-butyl 
(3-aminobenzyl)carbamate (96 mg, 0.43 mmol) yielded the Boc protected intermediate tert-
butyl-(3-((4-(tert-butyl)phenyl)sulfonamido)benzyl)carbamate (81 mg, 45% yield) as a white 
powder. The crude product was purified by silica flash column chromatography (column 
gradient of 5 to 50% EtOAc : Pet. ether 40-60 oC. 1H NMR (400 MHz, CDCl3) ) δ 7.81 – 7.65 
(m, 1H), 7.58 (s, 1H), 7.42 (d, J = 8.6 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.01 (dd, J = 17.0, 6.9 
Hz, 1H), 4.88 (s, 1H), 4.88 (s, 1H), 4.21 (d, J = 5.5 Hz, 1H), 4.19 (t, J = 14.4 Hz, 1H), 1.28 (s, 
5H). LC/MS [M-H]- found 416.8, purity >99%. 
To a solution of the Boc intermediate in dichloromethane (2 mL), trifluoroacetic acid (1 mL) 
was added dropwise and the mixture stirred for 0.5 hours. The reaction was quenched with 
saturated solution of NaHCO3. The organic phase was isolated, and the final product 
concentrated under reduced pressure to yield the desired compound 21 (55 mg, 89% yield) a 
white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.5 Hz, 
2H), 7.11 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 1.6 Hz, 1H), 6.93 (dd, J = 7.9, 1.9 Hz, 2H), 3.61 (s, 
2H), 1.25 (s, 9H); HRMS (ESI) calcd. for [C17H22N2O2S+H]+: 319.1467, Found: 319.1475; 




N-(3-(aminomethyl)phenyl)-2-(naphthalen-1-yl)ethane-1-sulfonamide (22). Using the same 
procedure as compound 28, tert-butyl (3-aminobenzyl)carbamate (87 mg, 0.393 mmol) and 2-
(naphthalen-1-yl)ethane-1-sulfonyl chloride (200 mg, 0.785 mmol, 2 equiv.) yielded the Boc 
intermediate (36 mg, 0.081 mmol, 21% yield) as a white powder. The crude product was 
purified by silica flash column chromatography (column gradient of 20% to 50% EtOAc : Pet. 
ether 40-60°C). 1H NMR (400 MHz, Chloroform-d) δ 7.86 (dd, J = 8.0, 1.4 Hz, 1H), 7.76 (t, J 
= 8.4 Hz, 2H), 7.54 – 7.32 (m, 4H), 7.20 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 7.9 Hz, 1H), 6.97 (dd, 
J = 8.0, 2.2 Hz, 1H), 6.81 (s, 1H), 6.59 (s, 1H), 4.82 (s, 1H), 4.20 (d, J = 6.1 Hz, 2H), 3.64 – 
3.53 (m, 2H), 3.51 – 3.40 (m, 2H), 1.44 (s, 9H); LCMS [M-H]- found 439.3, purity >99%. 
To a solution of the Boc intermediate (33 mg, 0.075 mmol) in dichloromethane (2 mL) 
trifluoroacetic acid (1 mL) was added dropwise and the mixture stirred for 0.5 hours. The 
reaction was quenched with saturated solution of NaHCO3. The organic phase was isolated, 
and the final product concentrated under reduced pressure to yield the desired compound 22 
(14.2 mg, 0.042 mmol, 56% yield) as colourless crystals. 1H NMR (400 MHz, Chloroform-d) 
δ 7.78 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.1 Hz, 2H), 7.46 – 7.20 (m, 4H), 7.13 (t, J = 7.7 Hz, 
1H), 7.06 – 6.93 (m, 3H), 5.30 (s, 1H), 5.04 (s, 2H), 3.80 (s, 2H), 3.58 – 3.45 (m, 2H), 3.43 – 
3.33 (m, 2H); HRMS (ESI) calcd. for [C19H20N2O2S + H]+: 341.1324, Found: 341.1343; LCMS 
[M-H]- found 339.1, purity >99%. 
 
N-(3-(aminomethyl)phenyl)-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide (23). Using 
the same procedure as compound 28, tert-butyl (3-aminobenzyl)carbamate (79 mg, 0.356 
mmol) and tert-butyl-(3-((5-chloro-3-methylbenzo[b]thiophene)-2-sulfonamido)benzyl)-
carbamate (100 mg, 0.356 mmol) yielded the Boc intermediate (156 mg, 0.334 mmol, 94% 
yield) as a colourless oil. The crude product was purified by silica flash column 
chromatography (column gradient of 30% to 60% EtOAc : Pet. ether 40-60 °C). 1H NMR (400 
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MHz, CDCl3) δ 8.08 (s, 1H), 7.64 (d, J = 8.7 Hz, 2H), 7.38 (dd, J = 8.7, 2.0 Hz, 1H), 7.17 (t, J 
= 7.8 Hz, 1H), 7.10 (s, 1H), 7.06 – 7.00 (m, 2H), 4.90 (s, 1H), 4.21 (d, J = 6.1 Hz, 2H), 2.41 (s, 
3H), 1.43 (s, 9H); 13C NMR (101 MHz, CDCl3) LC/MS [M-H]- found 465, purity 76%. 
To a solution of the Boc intermediate (147 mg, 0.315 mmol) in dichloromethane (2 mL), 
trifluoroacetic acid (1 mL) was added dropwise and the mixture stirred for 0.5 hours. The 
reaction was quenched with saturated solution of NaHCO3. The organic phase was isolated, 
and the final product concentrated under reduced pressure to yield the desired compound 23 
(115 mg, 0.315 mmol, 100% yield) as a white powder. 1H NMR (400 MHz, DMSO-d6) δ 7.87 
(dd, J = 8.5, 2.0 Hz, 1H), 7.72 (s, 1H), 7.35 (dd, J = 8.6, 2.1 Hz, 1H), 6.86 – 6.67 (m, 2H), 6.60 
(s, 1H), 6.47 (d, J = 7.4 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 3.92 (d, J = 6.1 Hz, 2H), 3.48 (s, 
2H), 2.46 (s, 3H); HRMS (ESI) calcd. for [C16H15ClN2O2S2+H]+: 367.0338, Found: 367.0342; 
LCMS [M-H]- found 365.1, purity >99%. 
 
N-(3-(aminomethyl)phenyl)-5-fluoro-3-methylbenzo[b]thiophene-2-sulfonamide (24). Using 
the same procedure as compound 28, tert-butyl-(3-aminobenzyl)carbamate (84 mg, 0.378 
mmol) and 5-fluoro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (100 mg, 0.378 mmol) 
yielded the Boc intermediate (125 mg, 0.277 mmol, 73% yield) as a white powder. The crude 
product was purified by silica flash column chromatography (column gradient of 20% to 50% 
EtOAc : Pet. ether 40-60 °C). 1H NMR (400 MHz, Chloroform-d) δ 8.25 (s, 1H), 7.66 (dd, J = 
8.8, 4.7 Hz, 1H), 7.36 – 7.28 (m, 1H), 7.22 – 6.94 (m, 5H), 4.92 (s, 1H), 4.20 (d, J = 5.7 Hz, 
2H), 2.40 (s, 3H), 1.42 (s, 9H); LCMS: [M-H]- found 449.1, purity >99%. 
To a solution of the Boc intermediate (161 mg, 0.358 mmol) in dichloromethane (2 mL), 
trifluoroacetic acid (1 mL) was added dropwise and the mixture stirred for 0.5 hours. The 
reaction was quenched with saturated solution of NaHCO3. The organic phase was isolated, 
and the final product concentrated under reduced pressure to yield the desired compound 24 
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(127 mg, 0.361 mmol, 99% yield) as a white powder. 1H NMR (400 MHz, DMSO-d6) δ 7.90 
(dd, J = 8.8, 5.1 Hz, 1H), 7.53 (dd, J = 10.1, 2.5 Hz, 1H), 7.24 (td, J = 8.9, 2.5 Hz, 1H), 7.03 – 
6.81 (m, 3H), 6.61 (d, J = 7.2 Hz, 1H), 3.67 (s, 2H), 2.46 (s, 3H); HRMS (ESI) calcd. For 
[C16H15FN2O2S2Na]+: 373.0451, Found: 373.0437; LCMS [M-H]- found 349.0, purity >99%. 
 
N-(3-(aminomethyl)phenyl)benzo[b]thiophene-2-sulfonamide (25). Using the same procedure 
as compound 7, tert-butyl (3-aminobenzyl)carbamate (96 mg, 0.430 mmol) and 
benzo[b]thiophene-2-sulfonyl chloride (100 mg, 0.430 mmol) yielded the Boc intermediate 
(158 mg, 0.338 mmol, 95% yield) as a white powder. The crude product was purified by silica 
flash column chromatography (column gradient of 20% to 50% EtOAc : Pet. Ether 40-60 °C). 
1H NMR (400 MHz, Chloroform-d) δ 8.33 (s, 1H), 7.80 – 7.69 (m, 3H), 7.44 – 7.30 (m, 2H), 
7.22 – 7.07 (m, 3H), 7.01 (d, J = 7.5 Hz, 1H), 4.96 (s, 1H), 4.22 (d, J = 6.1 Hz, 2H), 1.43 (s, 
9H); LCMS [M-H]- found 417.1, purity 93%. 
Using the same procedure as compound 19, the Boc intermediate (118 mg, 0.282 mmol) was 
deprotected to yield compound 25 (90 mg, 0.282 mmol, 99% yield) as a white powder. 1H 
NMR (400 MHz, DMSO-d6) δ 7.98 – 7.89 (m, 1H), 7.89 – 7.81 (m, 1H), 7.73 (s, 1H), 7.39 
(qd, J = 7.4, 3.7 Hz, 2H), 7.15 – 6.97 (m, 3H), 6.82 (d, J = 7.3 Hz, 1H), 3.83 (s, 2H), 2.68 (s, 
1H), 2.07 (s, 2H); HRMS (ESI) calcd. for [C15H14N2O2S2+H]+: 319.0569, Found: 319.0557; 
LCMS [M-H]- found 317.0, purity >99%. 
 
N-(3-(aminomethyl)phenyl)benzofuran-2-sulfonamide (26). Using the same procedure as 
compound 28, tert-butyl (3-aminobenzyl)carbamate (103 mg, 0.462 mmol) and benzofuran-2-
sulfonyl chloride (100 mg, 0.462 mmol) yielded the Boc intermediate (128 mg, 0.320 mmol, 
69% yield) as a white powder. The crude product was purified by silica flash column 
chromatography (column gradient of 20% to 50% EtOAc : Pet. ether 40-60 °C). 1H NMR (400 
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MHz, DMSO-d6) δ 10.93 (s, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.63 (s, 1H), 
7.51 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H), 7.37 (t, J = 7.1 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.10 (s, 
1H), 7.03 (d, J = 7.9 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H), 4.03 (d, J = 6.0 Hz, 2H), 1.37 (s, 9H), 
1.18 (s, 1H); HRMS (ESI) calcd. for [C20H21N2O5SNa+H]+: 425.1147, Found: 425.1146; 
LCMS: [M-H]- found 401.1, purity >99%. 
Using the same procedure as compound 19, the Boc-intermediate (103 mg, 0.256 mmol) was 
deprotected to yield compound 26 (51mg, 0.169 mmol, 66% yield) as a cream powder. 1H 
NMR (400 MHz, DMSO-d6) δ 7.63 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.34 (t, J = 
7.7 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.10 (s, 1H), 7.07 – 6.91 (m, 3H), 6.70 (d, J = 6.2 Hz, 
1H), 3.83 (s, 2H); HRMS (ESI) calcd. for [C15H14N2O3S+H]+: 303.0798, Found: 303.0786; 




The following files are available free of charge. 
Fragment hits identified by thermal shift (Table S1). X-ray crystallographic data collection 
and refinement statistics (Table S2) (PDF), Fo-Fc “Omit” maps of compounds 1, 2, 3, 4, 5, 
and 23 (Figure S1), X-ray crystal structures of fragment hits 1, 2, 3, 4 and 5 (Figure S2), 
Docking poses of compounds 23 and 24 (Figure S3). LCMS of all the compounds screened 
against InhA (Figure S4). 
Molecular formula strings (CSV) 
Accession Codes 
Atomic coordinates for the X-ray structures of compounds 1 (PDB code 6SQ5), 2 (PDB code 
6SQ7), 3 (PDB code 6SQ9), 4 (PDB code 6SQB), 5 (PDB code 6SQD) and 23 (PDB code 
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6SQL), are available from the RCSB Protein Data Bank (www.rcsb.org). Authors will release 
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